The increase in the price target by HC Wainwright & Co. reflects a positive outlook on SpringWorks Therapeutics' future performance. This endorsement from a reputable analyst firm could lead to increased investor confidence and potentially drive the stock price up in the short term. The decision to maintain a Buy rating further solidifies the optimistic view on the company's prospects.